Advanced hepatocellular Carcinoma Atezolizumab plus Bevacizumab - new First-Line Therapy Standard

被引：0
|
作者：
Vetter, Christine
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：429 / 429
页数：1
相关论文
共 50 条
  • [1] Advanced hepatocellular Carcinoma Atezolizumab and Bevacizumab Combination - New Standard First-Line Therapy
    Vetter, Christine
    VISCERAL MEDICINE, 2021, 37 (04) : 323 - 323
  • [2] Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Matono, Tomomitsu
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (08) : 1389 - 1397
  • [3] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
    Persano, M.
    Rimini, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Cheon, J.
    Finkelmeier, F.
    Presa, J.
    Masi, G.
    Yoo, C.
    Lonardi, S.
    Piscaglia, F.
    Iavarone, M. A.
    Tamburini, E.
    Cabibbo, G.
    Silletta, M.
    Cascinu, S.
    Scartozzi, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2023, 34 : S603 - S604
  • [4] Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Giri, Suprabhat
    Angadi, Sumaswi
    Vaidya, Arun
    Singh, Ankita
    Roy, Akash
    Sundaram, Sridhar
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 228 - 235
  • [5] First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Mahipal, Amit
    Jin, Zhaohui
    BIOMEDICINES, 2022, 10 (06)
  • [6] Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
    Shao, Yu-Yun
    Feng, Yin-Hsun
    Yen, Chia-Jui
    Yang, Tsai-Sheng
    Shen, Ying-Chun
    Chao, Yee
    Chen, Jen-Shi
    Su, Ching-Yen
    Chen, Wei-Jen
    Hsiang, Hwa-Lin
    Hsu, Chih-Hung
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (12) : 2430 - 2437
  • [7] First-Line Therapy with Bevacizumab - Standard in advanced Ovarian Carcinoma
    Pohlmann, Birgit-Kristin
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (06) : 382 - 383
  • [8] Is ageing a problematic hurdle to the efficacy of first-line atezolizumab plus bevacizumab in hepatocellular carcinoma?
    An, Jihyun
    Shim, Ju H.
    LIVER INTERNATIONAL, 2022, 42 (11) : 2352 - 2353
  • [9] Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study
    Storandt, Michael H.
    Zemla, Tyler J.
    Patell, Kanchi
    Naleid, Nikolas
    Gile, Jennifer J.
    Tran, Nguyen H.
    Chakrabarti, Sakti
    Jin, Zhaohui
    Borad, Mitesh
    Mahipal, Amit
    ONCOLOGIST, 2024, 29 (11): : 986 - 996
  • [10] Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
    C-H Hsu
    T-S Yang
    C Hsu
    H C Toh
    R J Epstein
    L-T Hsiao
    P-J Chen
    Z-Z Lin
    T-Y Chao
    A-L Cheng
    British Journal of Cancer, 2010, 102 : 981 - 986
12345